Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,916.25
(
0.87%
)
News Focus
News Focus
Post# of 257301
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 240052

Friday, 08/12/2022 11:00:59 AM

Friday, August 12, 2022 11:00:59 AM

Post# of 257301
PFE—Prevnar-20 hits_primary_endpoints_in phase-3 trial_in infants:

https://www.businesswire.com/news/home/20220812005073/en

The Prevnar franchise is PFE’s biggest seller not related to COVID. In the adult segment of the market, Prevnar-20 has achieved a 97% market share with MRK’s Vaxneuvance a very distant #2 (#msg-169520866, #msg-166441188).

The pediatric segment of the pneumococcal-vaccine market figures to be more competitive since MRK’s Vaxneuvance has a head start from its FDA approval in Jun 2022 (#msg-169208458).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today